

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.


×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[Back](#)

Search 

[About Us](#) [Our Mission, Vision & Treatment](#)

[The Cancer Genome](#) [About Cancer & Treatment](#)

×

## ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

## FOR THE MEDIA



**Lab Phone**

646-888-2649

**Email**

[alahmadh@mskcc.org](mailto:alahmadh@mskcc.org)

**URL**

[Physician Profile](#)

My research focuses on identifying the molecular and genetic characterizations of subsets of urothelial carcinoma that are associated with aggressive behavior such as small-cell carcinoma and plasmacytoid/signet ring-cell carcinoma, or those that harbor specific genetic aberrations that can be subjected to targeted therapy such as *FGFR3* mutations and Her2 amplification. Our findings support the presence of unique genotype-phenotype correlation in these subsets of bladder cancer, as in the case of tumors that harbor mutations in *FGFR3* and *CDH1*.

Recognizing this correlation may help to prospectively select patients for targeted therapy. We are also trying to determine the functional and clinical relevance of these alterations on tumor biology.

In addition, I am a collaborator on a number of research projects to define the genetic landscape of bladder cancer, both with investigators at our institution and in national efforts such as The Cancer Genome Atlas.

## Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Hikmat A. Al-Ahmadie discloses the following relationships and financial interests:

- AstraZeneca  
Professional Services and Activities
- Janssen Scientific Affairs, LLC  
Professional Services and Activities
- Pfizer, Inc.  
Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#) . For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org) .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

